Exelixis - EXEL Stock Forecast, Price & News

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Analysts Set New Price Targets

Several analysts have commented on the stock. Piper Sandler lifted their target price on shares of Exelixis from $30.00 to $32.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 26th. BMO Capital Markets began coverage on shares of Exelixis in a research note on Thursday, June 23rd. They set an "outperform" rating and a $28.00 price objective for the company. Jefferies Financial Group began coverage on shares of Exelixis in a research note on Thursday, May 12th. They set a "buy" rating and a $28.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Exelixis from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Friday, July 15th. Finally, StockNews.com cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 18th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.56.

Exelixis Trading Down 0.5 %

NASDAQ:EXEL opened at $19.22 on Friday. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 22.88, a PEG ratio of 0.60 and a beta of 0.60. The firm's fifty day simple moving average is $20.57 and its 200 day simple moving average is $20.58. Exelixis has a twelve month low of $15.50 and a twelve month high of $23.40.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 18,812 shares of the business's stock in a transaction on Friday, May 27th. The shares were sold at an average price of $18.21, for a total value of $342,566.52. Following the transaction, the executive vice president now owns 239,818 shares in the company, valued at approximately $4,367,085.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.90% of the stock is currently owned by company insiders.